Mohammed Aminu, Koorbanally Neil Anthony, Islam Md Shahidul
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville Campus), Durban 4000, South Africa; Department of Biochemistry, Faculty of Science, Ahmadu Bello University, Zaria, Nigeria.
Department of Chemistry, School of Chemistry and Physics, University of KwaZulu-Natal, (Westville Campus), Durban 4000, South Africa.
J Ethnopharmacol. 2016 Mar 2;180:131-9. doi: 10.1016/j.jep.2016.01.009. Epub 2016 Jan 12.
In traditional medicine from West Africa, the fruit decoction of Xylopia aethiopica (Dunal) A. Rich. is widely used for the treatment of diabetes mellitus (DM) either alone or in combination with other plants. The present study is designed to investigate the anti-diabetic effects of X. aethiopica acetone fraction (XAAF) from fruit ethanolic extract in a type 2 diabetes (T2D) model of rats.
T2D was induced in rats by feeding a 10% fructose solution ad libitum for 2 weeks followed by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight) and the animals were orally treated with 150 or 300 mg/kg body weight (bw) of the XAAF once daily for four weeks.
After 4 weeks study period, diabetic untreated animals (DBC) exhibited significantly higher serum glucose, serum fructosamine, LDH, CK-MB, serum lipids, liver glycogen, insulin resistance (HOMA-IR), AI, CRI and lower serum insulin, β-cell function (HOMA-β) and glucose tolerance ability compared to the normal animals. Histopathological examination of their pancreas revealed corresponding pathological changes in the islets and β-cells. These alterations were reverted to near-normal after the treatment of XAAF at 150 (DXAL) and 300 (DXAH) mg/kg bw with the effects being more pronounced in the DXAH group compared to the DXAL group. Moreover, the effects in the animals of DXAH group were comparable to the diabetic metformin (DMF) treated animals. In addition, no significant alterations were observed in non-diabetic animals treated with 300 mg/kg bw of XAAF (NXAH).
The results of our study suggest that XAAF treatment showed excellent anti-diabetic effects in a T2D model of rats.
在西非传统医学中，埃塞俄比亚木瓣树（Xylopia aethiopica (Dunal) A. Rich.）的果实煎剂被广泛用于治疗糖尿病（DM），可单独使用或与其他植物联合使用。本研究旨在研究从果实乙醇提取物中获得的埃塞俄比亚木瓣树丙酮提取物（XAAF）在大鼠2型糖尿病（T2D）模型中的抗糖尿病作用。
通过随意喂食10%果糖溶液2周，随后单次腹腔注射链脲佐菌素（40 mg/kg体重）诱导大鼠患T2D，然后动物每天口服150或300 mg/kg体重（bw）的XAAF，持续4周。
经过4周的研究期，未治疗的糖尿病动物（DBC）与正常动物相比，血清葡萄糖、血清果糖胺、乳酸脱氢酶（LDH）、肌酸激酶同工酶（CK-MB）、血脂、肝糖原、胰岛素抵抗（HOMA-IR）、动脉硬化指数（AI）、心血管风险指数（CRI）显著更高，而血清胰岛素、β细胞功能（HOMA-β）和葡萄糖耐量能力更低。对其胰腺进行组织病理学检查发现胰岛和β细胞有相应的病理变化。在用150（DXAL）和300（DXAH）mg/kg bw的XAAF治疗后，这些改变恢复到接近正常，与DXAL组相比，DXAH组的效果更明显。此外，DXAH组动物的效果与糖尿病二甲双胍（DMF）治疗的动物相当。此外，用300 mg/kg bw的XAAF治疗的非糖尿病动物（NXAH）未观察到明显变化。
我们的研究结果表明，XAAF治疗在大鼠T2D模型中显示出优异的抗糖尿病作用。
